Skip to main content
Caplight Logo









Waypoint Bio

Waypoint Bio

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.waypointbio.com/

Last Round

Series A

May 27, 2026

Total Funding Raised

$34.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Waypoint Bio is a biotechnology company that develops next-generation cell therapies for solid tumors using a proprietary spatial pooled screening platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoveryfunctional genomicsai drug discoverytarget identificationhigh-throughput screeningin silico drug discoveryspatial genomicspredictive modelingbiotech platformtarget validationcomputational biologydrug developmentgenotype-phenotype mappingai-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Waypoint Bio Comparables

Compare Waypoint Bio with similar companies based on industry and business-model similarity.

Waypoint Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tahoe Therapeutics
83%
Insitro
80%
Gordian Biotechnology
78%

Waypoint Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 27, 2026
SeedJun 28, 2024

Key People

Founding team and executive leadership

Xinchen Wang

Co-founder And CEO

Founding Team

Patrick Kaifosh

Chief Technology Officer

Executive Team

Waypoint Bio Investors

Notable investors and investment history

Waypoint Bio investors
InvestorRounds
Time BioVenturesSeries A
Mitsui Global InvestmentSeries A
Lux CapitalSeries A
General CatalystSeries A
Amplify PartnersSeries A
Fifty YearsSeed
Recode VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 72% MoM, reaching 3.7K.

  • May 27, 2026

    $20M round led by Amplify Partners.

Waypoint Bio Filings

Explore SEC and related filing metadata, where available.

Waypoint Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Waypoint Bio's valuation, stock price, and market status.

Is Waypoint Bio a public or private company?

Waypoint Bio is a private company.

What is the current stock price of Waypoint Bio?

Waypoint Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Waypoint Bio worth (valuation)?

Valuation information for Waypoint Bio is not publicly available.

Can I buy Waypoint Bio stock?

Waypoint Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Waypoint Bio's last funding round?

Waypoint Bio's most recent funding round was Series A on June 1, 2026.

Who are the main investors in Waypoint Bio?

Key investors in Waypoint Bio include Amplify Partners, Hummingbird Ventures.

Will Waypoint Bio IPO soon?

No public IPO plans have been announced for Waypoint Bio.

How can I track Waypoint Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Waypoint Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range20
Year Founded2021
Last FundingMay 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?